Mediera Corporation (TPEX:5398)
Taiwan · Delayed Price · Currency is TWD 22.00
+1.15 (5.52%)
Mar 26, 2026, 1:30 PM CST
Mediera Revenue
In the year 2025, Mediera had annual revenue of 229.85M TWD, down -3.62%. Mediera had revenue of 55.56M in the quarter ending December 31, 2025, a decrease of -15.83%.
Revenue
229.85M
Revenue Growth
-3.62%
P/S Ratio
4.73
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 229.85M | -8.64M | -3.62% |
| Dec 31, 2024 | 238.48M | 45.59M | 23.63% |
| Dec 31, 2023 | 192.90M | -64.65M | -25.10% |
| Dec 31, 2022 | 257.55M | -94.01M | -26.74% |
| Dec 31, 2021 | 351.56M | -16.33M | -4.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Excelsior Biopharma | 898.26M |
| Anxo Pharmaceutical | 883.22M |
| Prince Pharmaceutical | 798.27M |
| Winston Medical Supply | 724.35M |
| DV Biomed | 712.61M |
| GeneFerm Biotechnology | 677.10M |
| Tien Liang BioTech | 511.79M |
| Bioray Biotech | 230.06M |